On May 1, 2025, aTyr Pharma, Inc. held its Annual Meeting where shareholders approved increasing the shares in the stock option plan by 5 million to 15.7 million and elected directors. All proposals, including appointing Ernst & Young as auditors and approving executive compensation, received majority votes with over 69 million shares represented.